公开(公告)号：US20240300897A1

公开(公告)日：2024-09-12

申请号：US18657052

申请日：2024-05-07

Applicant: Exelixis, Inc.

Inventor： Frenel DeMorin ,  Khalid Shah ,  Sagar Shakya ,  Peter Wong ,  Courtney S. Johnson ,  Melanie Janelle Bevill ,  Stephan D. Parent

IPC: C07D215/48

CPC classification number: C07D215/48 ,  C07B2200/13

Abstract: The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.

公开(公告)号：US20230192619A1

公开(公告)日：2023-06-22

申请号：US17922208

申请日：2021-04-30

Applicant: Exelixis, Inc.

Inventor： Frenel DeMorin ,  Khalid Shah ,  Sagar Shakya ,  Yong Wang ,  Wei Xu

IPC: C07D215/48

CPC classification number: C07D215/48

Abstract: The present invention relates to processes for the synthetic preparation of c-Met inhibitors of Formula I, or pharmaceutically acceptable salts thereof. The present invention further relates to processes for the synthetic preparation of the c-Met inhibitor, Compound 1, or a pharmaceutically acceptable salt thereof. The present invention also relates to processes for the synthetic preparation of Compound 1.hemifumarate. The invention further relates to large scale processes for the synthetic preparation of the c-Met inhibitor, Compound 1 and Compound 1.hemifumarate.

公开(公告)号：US12017995B2

公开(公告)日：2024-06-25

申请号：US17312658

申请日：2019-12-12

Applicant: Exelixis, Inc.

Inventor： Frenel DeMorin ,  Khalid Shah ,  Sagar Shakya ,  Peter Wong ,  Courtney S. Johnson ,  Melanie Janelle Bevill ,  Stephan D. Parent

IPC: C07D215/48 ,  A61K31/47

CPC classification number: C07D215/48 ,  C07B2200/13

Abstract: The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.

公开(公告)号：US20230029213A1

公开(公告)日：2023-01-26

申请号：US17312658

申请日：2019-12-12

Applicant: Exelixis, Inc.

Inventor： Frenel DeMorin ,  Khalid Shah ,  Sagar Shakya ,  Peter Wong ,  Courtney S. Johnson ,  Melanie Janelle Bevill ,  Stephan D. Parent

IPC: C07D215/48

Abstract: The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.

公开(公告)号：US20230052703A1

公开(公告)日：2023-02-16

申请号：US17616124

申请日：2019-12-12

Applicant: Exelixis, Inc.

Inventor： Frenel DeMorin ,  Khalid Shah ,  Sagar Shakya ,  Peter Wong ,  Courtney S. Johnson ,  Melanie Janelle Bevill ,  Stephan D. Parent

IPC: C07D215/48

Abstract: The present invention relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid crystalline salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.